Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cenestin · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Cenestin 0.3 mg Tablets | DRUG | 1 tablet daily |
| Placebo | OTHER | 1 tablet daily |
Inclusion Criteria: * Naturally or surgically postmenopausal * At least 12 months since last menses or 6 weeks past surgery * Minimum of 7 daily or 50 weekly moderate to severe hot flashes Exclusion Criteria: * Any contraindication to natural or synthetic estrogens
Cenestin is a small molecule drug being developed for the treatment of hot flashes, a symptom commonly associated with menopause. It is an investigational therapy that has been studied in a clinical trial setting, though it is not yet approved for this use.
Cenestin is being developed by Teva Pharmaceutical Industries Limited, a company publicly traded under the ticker symbol TEVA. Teva is responsible for the clinical development of this drug candidate for the treatment of hot flashes.
Cenestin is in Phase 3 clinical development. It has completed a Phase 3 trial, but it remains an investigational drug and has not been approved by regulatory authorities for the treatment of hot flashes.
Cenestin has been studied in a completed Phase 3 clinical trial registered as NCT00272935. This trial, titled "A Clinical Trial to Demonstrate the Efficacy and Safety of Cenestin 0.3 mg for the Treatment of Hot Flashes," enrolled 400 female participants aged 30 years and older in the United States.
Yes, the Phase 3 clinical trial for Cenestin was a randomized, double-blind, placebo-controlled study. This design was used to evaluate the efficacy and safety of Cenestin 0.3 mg for the treatment of hot flashes in the 400 enrolled participants.